Navigation Links
Arpida Announces Agenda Items for Shareholders Meeting
Date:4/15/2008

authorised capital) or via conversion of bonds (conditional capital). Arpida currently has no intention to use this capital. This proposed additional capital cannot be used for the granting of employee options.

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent antibacterial that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The clinical programme for the first indication, complicated skin and skin structure infections (cSSSI), has been completed. The submission of the NDA to the US FDA was completed in March 2008.

In December 2007, Arpida announced the enrolment of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch could be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resi
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
2. Arpida Announces Full Year 2007 Financial Results
3. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
4. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
5. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
6. Arpida-Supported CME Symposium Available Online
7. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
8. Arpida Presents Preclinical Data on AR-2474 at ICAAC
9. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
10. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
11. Arpida Interim Results for six Months to 30 June 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 The Microcompetition with Foreign DNA ... disease. One of these latent viruses is the Epstein ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... by the theory, a study found that RA patients ... (1). , What is Microcompetition? , Dr. Hanan ...
(Date:1/15/2014)... Sunnyvale, CA (PRWEB) January 15, 2014 ... of high throughput research solutions, today announced that ... companies, has received delivery of Freeslate’s CM ... form screening. , Lupin, headquartered in Mumbai, ... quality, affordable generic and branded formulations and Active ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, ... Foundation, the only national nonprofit organization solely dedicated to ... quality of life for those affected worldwide, will host ... Warrington Country Club in Warrington, Pa. , Each ...
(Date:1/14/2014)... , Jan. 14, 2014  3D Communications, a leading provider ... major scientific, regulatory, business, and media events in ... , today announced its former associate Virginia Cox , ... office. Virginia Cox re-joins ... Commissioner for the Office of External Affairs at the U.S. ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2Former FDA Associate Commissioner Returns To 3D Communications 2
... net loss in 2007, Hutchinson Technology , a Minnesota-based ... Claire manufacturing plant, according to a report in the ... plant are part of an overall workforce reduction of 500 ... and Sioux Falls, S.D. The company is headquartered in Hutchinson, ...
... first in a four-part series of articles regarding the rules ... particular, the discovery of electronically stored information, or ESI. In ... Michael Best and Friedrich will highlight the rule changes, ... , , Recently, the Federal Rules of Civil ...
... it was founded in 1998, EMSystem has grown ... communications and resource management for hospitals and emergency services providers. ... stature or gotten off the ground at all had it ... the words of one of its founders, one of those ...
Cached Biology Technology:Quick peeks, Clawback Agreements, and the rules of electronic discovery 2Quick peeks, Clawback Agreements, and the rules of electronic discovery 3Pre-eminent, web-based companies owe success to corporate venturing 2Pre-eminent, web-based companies owe success to corporate venturing 3Pre-eminent, web-based companies owe success to corporate venturing 4Pre-eminent, web-based companies owe success to corporate venturing 5Pre-eminent, web-based companies owe success to corporate venturing 6
(Date:4/15/2014)... Space Flight Center in Greenbelt, Md., is home ... support staff. At Goddard, some of the most ... and some of that cutting-edge innovation has earned ... The Swedish Society for Anthropology and Geography awards ... person who has shown excellence in the fields ...
(Date:4/15/2014)... at UC San Diego have succeeded in visualizing ... responsible for growth and resistance to drought. The ... to determine how the hormone helps plants respond ... the continuing increase in the atmosphere,s carbon dioxide, ... appears in the April 15 issue of the ...
(Date:4/15/2014)... some of the loveliest in the world, but they ... pasture soils have become enriched in cadmium. Grasses take ... by the cattle and sheep that graze them. The ... being reported worldwide. , The concern is that if ... dairy products, human health and New Zealand,s agricultural economy ...
Breaking Biology News(10 mins):Goddard scientist receives Vega Medal from King of Sweden 2Biologists develop nanosensors to visualize movements and distribution of plant hormone 2
... construction can be significantly improved to reduce wind pressures ... winds and hurricanes in residential or commercial construction, said ... is also a civil/structural engineer, teaches at the New ... topics related to wind and earthquakes with guidelines and ...
... Spanish . Barcelona, Spain: For ... developing human embryonic stem cells (hESCs) from a single cell, ... conference of the European Society of Human Reproduction and Embryology ... from the Vrije Universiteit Brussel (VUB), Brussels, Belgium, said that ...
... bioMETRX Inc., (OTC,Bulletin Board: BMRX), today announced that ... its former competitor, Sequiam Corporation. The company also,announced ... assets into the,company,s technology portfolio and consumer based ... under the company,s smartTOUCH,brand., The purchase price ...
Cached Biology News:NJIT architect professor advocates best-building practices for high wind regions 2Human embryonic stem cells developed from 4-cell embryo; world first may lessen ethical concerns 2Human embryonic stem cells developed from 4-cell embryo; world first may lessen ethical concerns 3Human embryonic stem cells developed from 4-cell embryo; world first may lessen ethical concerns 4bioMETRX, Inc. Completes Sequiam Asset Purchase 2
... solution is an isotonic, balanced salt solution. It ... permits the storage of whole blood at refrigerator ... equal volume of blood is collected into a ... mixed. The solution is placed in a refrigerator ...
... Hollandes is a fixative useful for routine ... It is stable and will decalcify small ... Hollande's can be stained successfully with most ... solution stabilizes red blood cell membranes and ...
... a single-channel sample processing head, an 8-channel ... dispenser all in one compact, affordable product. ... tips, the Precision XS autoclavable and organic ... for transferring larger volumes. Intuitive Precision Power ...
... The RapidPlate 96/384 workstation offers precise 96 ... scalable format. Utilizing 100ul and 200ul disposable ... delivers excellent accuracy and precision across a ... rotary deck includes two positions that enable ...
Biology Products: